Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Molecular Therapy (Impact Factor: 6.23). 11/2007; 15(11):2044-50. DOI: 10.1038/
Source: PubMed


Immunity to self antigens on cancer is constrained by tolerance/ignorance. DNA vaccines encoding xenogeneic differentiation antigens, such as tyrosinase (TYR), mediate tumor protection and regression in implantable mouse models, and dogs with spontaneous melanoma. We conducted a trial of mouse and human TYR DNA vaccines in stage III/IV melanoma patients. Eighteen human leukocyte antigen (HLA)-A*0201(+) melanoma patients were randomized as follows: one group received three mouse TYR DNA injections followed by three human TYR DNA injections; the other group received the same vaccines in opposite sequence. The study was conducted at three dose levels: 100, 500, and 1,500 microg DNA/injection, administered intramuscularly (IM) every 3 weeks. Most toxicities were grade 1 injection site reactions. Seven patients developed CD8(+) T-cell responses, defined by a >3 SD increase in baseline reactivity to TYR peptide in tetramer or intracellular cytokine staining (ICS) assays. There was found to be no relationship between dose, assigned schedule, and T-cell response. At a median of 42 months follow-up, median survival has not been reached. Mouse and human TYR DNA vaccines were found safe and induced CD8(+) T-cell responses in 7 of 18 patients. T cells recognizing a native TYR peptide had a phenotype consistent with that of effector memory cells.

Download full-text


Available from: Jianda D Yuan, May 23, 2014
  • Source
    • "Conversely, increasing the dose has not always been correlated with greater antigenicity. Many clinical trials have evaluated the impact of dose escalation and there was found to be no direct relationship between dose and immune response [19-21]. Still, reduction of antigen below a minimal threshold can bring the response to a halt and in contrast, persistence of the antigen may stop the immune response through the deletion of effector cells [22]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT: The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides. The vaccine is intended to induce antibodies against self EGF that would block EGF-EGFR interaction. CimaVax-EGF has been evaluated so far in more than 1000 advanced NSCLC patients, as second line therapy. Two separate studies were compared to assess the impact of high dose vaccination at multiple anatomic sites in terms of immunogenicity, safety and preliminary efficacy in stage IIIb/IV NSCLC patients. In both clinical trials, patients started vaccination 1 month after finishing first line chemotherapy. Vaccination at 4 sites with 2.4 mg of EGF (high dose) was very safe. The most frequent adverse events were grade 1 or 2 injection site reactions, fever, headache and vomiting. Patients had a trend toward higher antibody response. The percent of very good responders significantly augmented and there was a faster decrease of circulating EGF. All vaccinated patients and those classified as good responders immunized with high dose at 4 sites, had a large tendency to improved survival.
    Journal of Immune Based Therapies and Vaccines 10/2011; 9(1):7. DOI:10.1186/1476-8518-9-7
  • Source
    • "Application of xenogeneic tumor-associated antigens is another interesting strategy to overcome some of the obstacles mentioned above. The magnitude of an antitumor response is clearly improved by using a tumor-associated antigen obtained from a different species sharing critical epitopes flanked by xenogeneic protein sequences further stimulating the antitumor response [16] [17] [18] [19]. The delivery of such xenogeneic tumor-associated antigens by DNA vaccination may be a promising venue to the design of a successful strategy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is one of the most challenging diseases of today. Optimization of standard treatment protocols consisting of the main columns of chemo- and radiotherapy followed or preceded by surgical intervention is often limited by toxic side effects and induction of concomitant malignancies and/or development of resistant mechanisms. This requires the development of therapeutic strategies which are as effective as standard therapies but permit the patients a life without severe negative side effects. Along this line, the development of immunotherapy in general and the innovative concept of DNA vaccination in particular may provide a venue to achieve this goal. Using the patient's own immune system by activation of humoral and cellular immune responses to target the cancer cells has shown first promising results in clinical trials and may allow reduced toxicity standard therapy regimen in the future. The main challenge of this concept is to transfer the plethora of convincing preclinical and early clinical results to an effective treatment of patients.
    Clinical and Developmental Immunology 12/2010; 2010(1740-2522):169484. DOI:10.1155/2010/169484 · 2.93 Impact Factor
  • Source
    • "Given that patients were injected with double-stranded DNA, we measured anti-nuclear anti-DNA antibodies (Hep-2 indirect fluorescence assay) during and after treatment. Similar to prior DNA vaccination trials,14,18 we did not detect any persistent elevation of anti-DNA antibodies. In accordance with FDA guidelines for gene transfer studies, all patients are being followed for 15 years as surveillance for second malignancies, neurologic or autoimmune disease. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances immune responses by inducing proliferation, maturation, and migration of dendritic cells (DCs) as well as expansion and differentiation of B and T lymphocytes. The potency of DNA vaccines can be enhanced by the addition of DNA encoding cytokines, acting as molecular adjuvants. We conducted a phase I/II trial of human GM-CSF DNA in conjunction with a multipeptide vaccine (gp100 and tyrosinase) in stage III/IV melanoma patients. Nineteen human leukocyte antigen (HLA)-A*0201+ patients were treated. Three dose levels were studied: 100, 400, and 800 microg DNA/injection, administered subcutaneously every month with 500 microg of each peptide. In the dose-ranging study, three patients were treated at each dose level. The remaining patients were then treated at the highest dose. Most toxicities were grade 1 injection-site reactions. Eight patients (42%) developed CD8+ T-cell responses, defined by a > or =3 SD increase in baseline reactivity to tyrosinase or gp100 peptide in tetramer or intracellular cytokine staining (ICS) assays. There was no relationship between dose and T-cell response. Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant.
    Molecular Therapy 10/2008; 16(12):2022-9. DOI:10.1038/mt.2008.196 · 6.23 Impact Factor
Show more